NEWS

News

January

Philogen announces the completion of a second interim analysis of its phase III clinical program with NidlegyTM for the treatment of melanoma

 

  Press Release

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all of the cookies, please refer to the cookie policy. By closing this banner, scrolling this page, clicking a link or continuing to browse otherwise, you agree to the use of cookies.

I Accept Cookie Policy
X